TP53 and cholangiocarcinoma: TP53-mutated CCA patients displayed significantly poorer OS than those with wild-type TP53 genes (mOS: 13.7 vs. 36.6 months, HR: 2.23, 95% CI: 1.67–2.99, Figure S1c).